[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651579":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":26,"locations":11,"responsibleParty":32,"collaborators":11,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":11,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":11,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":11},{"fullName":5,"class":6},"Antalya City Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Level Intertransverse Process Block","ACTIVE_COMPARATOR",null,[13],"Procedure: Single Level Intertransverse Process Block",{"label":15,"type":10,"description":11,"interventionNames":16},"Multiple Level Intertransverse Process Block",[17],"Procedure: Multiple Level Intertransverse Process Block",[19,23],{"type":20,"name":15,"description":21,"armGroupLabels":22,"otherNames":11},"PROCEDURE","Using an in-plane approach, a 21G 0.8×100 mm echogenic insulated needle (Echoplex®+, Vygon SA, Écouen, France) will be advanced from lateral to medial, with the needle tip positioned immediately posterior to the SCTL at each intertransverse level. Proper needle placement will be confirmed by injection of 1-2 mL isotonic saline and sonographic visualization of appropriate injectate spread and anterior displacement of the pleura. Upon confirmation and negative aspiration, 5 mL of 0.25% bupivacaine hydrochloride (Buvasin®, Vem Pharmaceuticals, Turkey) will be administered at each of the T2-T3, T3-T4, T4-T5, and T5-T6 levels, resulting in a total volume of 20 mL.",[15],{"type":20,"name":9,"description":24,"armGroupLabels":25,"otherNames":11},"Using an in-plane approach, a 21G 0.8×100 mm echogenic insulated needle (Echoplex®+, Vygon SA, Écouen, France) will be advanced from lateral to medial, with the needle tip positioned immediately posterior to the SCTL at the T4-T5 intertransverse level. Proper needle placement will be confirmed by injection of 1-2 mL isotonic saline and sonographic visualization of appropriate injectate spread and anterior displacement of the pleura. Upon confirmation and negative aspiration, 20 mL of 0.25% bupivacaine hydrochloride (Buvasin®, Vem Pharmaceuticals, Turkey) will be administered.",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"MUSTAFA KILIN, CONSULTANT ANESTHESİOLOGİST","CONTACT","+905464569218","mustafa.kilin90@gmail.com",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Mustafa Kılın","consultant anesthesiology","100651579","single-vs-multiple-injection-intertransverse-process-block-in-breast-cancer-surgery-100651579",false,"NCT07763756","Single vs Multiple Injection Intertransverse Process Block in Breast Cancer Surgery","Comparison of Single-Injection and Multiple-Injection Intertransverse Process Block for Postoperative Analgesia in Breast Cancer Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* ASA physical status I-III\n* Scheduled for elective breast cancer surgery\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Ability to understand and use the patient-controlled analgesia (PCA) device\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Allergy to local anesthetics\n* Infection at the injection site\n* Coagulopathy or ongoing anticoagulant therapy\n* Chronic opioid use or opioid dependence\n* Severe hepatic or renal insufficiency\n* Pregnancy or breastfeeding\n* Cognitive impairment or inability to communicate pain scores\n* Body mass index (BMI) \\\u003C18 or \\>35 kg\u002Fm²","FEMALE","18 Years","65 Years",{"count":47,"type":48},60,"ESTIMATED","INTERVENTIONAL",[51],"NA","This randomized clinical trial aims to evaluate and compare the analgesic efficacy of single Intertransverse Process Block (ITP) and multiple Intertransverse Process Block (ITP) in patients undergoing Breast Cancer Surgery. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire.",[54,55,56,57,58],"Breast Cancer","Postoperative Pain","Mastectomy","Regional Anaesthesia","Intertransverse Process Block",[60,58],"ITP","NOT_YET_RECRUITING","2026-08-09",{"date":64,"type":65},"2026-08-13","ACTUAL",{"date":67,"type":48},"2026-11-01",{"date":69,"type":48},"2027-09-01",{"name":5,"class":6}]